KlaymanToskes Continues Investigating CNL Healthcare Properties REIT
National investment loss lawyers KlaymanToskes continues its investigation of brokerage firms and financial advisors that made unsuitable recommendations to invest in CNL Healthcare Properties to their customers.
The announcement follows CNL Healthcare’s filing of its most recent Form 8-K with the SEC, disclosing that its Board of Directors approved its Fourth Amendment to its Advisory Agreement. The filing also disclosed that its Board renewed CNL’s Advisory Agreement for an additional two years ending June 30, 2025. Financial professionals who recommended CNL Healthcare may be responsible for any investment losses incurred.
If your financial advisor recommended an unsuitable Real Estate Investment Trust (“REIT”) investment based on your investment profile, or disregarded your risk-tolerance when making investment recommendations, you may be entitled to a financial recovery through FINRA arbitration.
Investors who suffered losses in CNL Healthcare Properties due to their broker/financial advisor are encouraged to contact attorney Lawrence L. Klayman at (888) 997-9956 or investigations@klaymantoskes.com for a free and confidential consultation to discuss potential recovery options. We do not collect attorney’s fees unless we are able to obtain a financial recovery for you.
CNL Healthcare REIT Timeline Summary:
CNL Healthcare Properties is “a non-traded Real Estate Investment Trust (REIT) that seeks to provide income and growth” according to its website. The following is a timeline of CNL Healthcare Properties’ recent events which investors should be aware of:
-
-
June 26, 2018: CNL filed a Form 8-K and notified stockholders that it suspended its Distribution Reinvestment Program (DRP) and Stock Redemption Plan (SRP) (SRP suspension became effective July 11, 2018).
-
February 10, 2021: Comrit Investments 1 LP launched a tender offer to buy up to 8.8 million shares for $3.66 per share (cash) (offer materials indicated an expiration of March 30, 2021).
-
February 28, 2023: Comrit filed a pre-commencement Schedule TO describing a proposed tender offer price of $4.64 per share.
-
March 2023: CNL disclosed that Comrit’s then-current offer was $4.36 per share and CNL’s board recommended that stockholders reject the tender offer.
-
December 31, 2022 (NAV announced): CNL reported an estimated NAV of $6.92 per share as of 12/31/2022.
-
June 5, 2023: CNL filed an 8-K reporting approval of a Fourth Amendment to its Advisory Agreement (effective June 8, 2023) and renewal of the Advisory Agreement through June 30, 2025.
-
January 2024: Reports indicated Comrit launched another tender offer at $3.94 per share (with an announced expiration of March 6, 2024). (AltsWire).
-
December 31, 2023 (NAV announced March 12, 2024): CNL reported an estimated NAV of $6.28 per share as of 12/31/2023. CNL Healthcare Properties
-
February 2025: CNL urged stockholders to reject an unsolicited tender offer from West 4 Capital at $3.29 per share. CNL Healthcare Properties
-
December 31, 2024 (NAV announced March 11, 2025): CNL reported an estimated NAV range of $6.33–$6.98, with a midpoint of $6.64 per share used for stockholder statements. CNL Healthcare Properties
-
April 8, 2025: A Comrit-related tender offer disclosure advertised a cash offer of $3.03 per share (materials referenced an expiration of June 5, 2025).
-
November 5, 2025: Sonida Senior Living (NYSE: SNDA) announced a definitive merger agreement to acquire 100% of CNL in a cash-and-stock deal valued at approximately $1.8 billion, equating to about $6.90 per CNL share. Consideration disclosed: $2.32 cash + $4.58 in Sonida stock value, with the stock portion subject to an asymmetric collar (exchange ratio min/max 0.1318x–0.2015x; collar reference points $22.73 and $34.76). The companies indicated an expected close late Q1 or early Q2 2026, subject to approvals. SEC Sonida Senior Living
-
CNL Healthcare Properties Investors May Have Recovery Options
REITs such as CNL Healthcare Properties are generally considered to be more complex than traditional investments such as stocks, bonds, and mutual funds, and involve a high degree of risk due to being illiquid. Brokers, investment advisors and their firms are responsible for providing suitable investment advice and for disclosing all of the risks and rewards of an investment to the customer.
In the event that a misrepresentation or omission of material facts results in losses suffered by the investor, the brokerage firm may be held liable in a FINRA arbitration claim. Conflicts of interest may include financial advisors offering or recommending financial products or services based on financial incentives such as commission, and/or the financial advisor failing to make recommendations with the customer’s best interest in mind.
Investors that suffered significant losses in CNL Healthcare Properties due to their brokerage firm and/or financial advisor should contact attorney Lawrence L. Klayman, Esq., at 888-997-9956, or investigations@klaymantoskes.com to discuss their potential recovery options.
Consultations are free and every case is taken on a contingency basis, meaning we do not collect a fee unless we are able to obtain a financial recovery for you.
About KlaymanToskes
KlaymanToskes is a leading national securities law firm which practices exclusively in the field of securities arbitration on behalf of retail and institutional investors throughout the world in large and complex securities matters. The firm has recovered over $250 million in FINRA arbitrations and over $350 million in other securities litigation matters. KlaymanToskes has office locations in California, Florida, Nebraska, New York, and Puerto Rico.
Contact
KlaymanToskes, P.A.
Lawrence L. Klayman, Esq.
888-997-9956
investigations@klaymantoskes.com
www.klaymantoskes.com
